Overview

Study of Methylnaltrexone (MNTX) for the Relief of Constipation

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy of subcutaneous MNTX to relieve opioid-induced constipation in patients with advanced medical illness.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Methylnaltrexone
Naltrexone